Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR

European Journal of Pharmacology

Volumn 558, Issue 1-3, 2007, Pages 14-20

  Jin, Soo Hyun ^a   Kim, Tae Il ^a   Yang, Kyoung Min ^a   Kim, Won Ho ^a  

^a Yonsei University   (South Korea)

Author keywords

Cyclooxygenase 2; HuR (Hu antigen R); mRNA stability; p38 MAPK (p38 mitogen activated protein kinase); Thalidomide

Indexed keywords

CYCLOOXYGENASE 2; HUR PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; THALIDOMIDE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG INHIBITION; ENZYME STABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; RNA DEGRADATION; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION;

ANTIGENS, SURFACE; CACO-2 CELLS; CYCLOOXYGENASE 2; CYTOPLASM; HUMANS; IMIDAZOLES; INTERLEUKIN-1BETA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN TRANSPORT; PYRIDINES; RNA STABILITY; RNA-BINDING PROTEINS; THALIDOMIDE;

EID: 33847358697     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.060     Document Type: Article

References (57)

1. Anant S., Henderson J.O., Mukhopadhyay D., Navaratnam N., Kennedy S., Min J., and Davidson N.O. Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor. J. Biol. Chem. 276 (2001) 47338-47351
2. Barlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev., Cancer 4 (2004) 314-322
3. Brennan C.M., and Steitz J.A. HuR and mRNA stability. Cell. Mol. Life Sci. 58 (2001) 266-277
4. Caponigro G., and Parker R. Mechanisms and control of mRNA turnover in Saccharomyces cerevisiae. Microbiol. Rev. 60 (1996) 233-249
5. Caput D., Beutler B., Hartog K., Thayer R., Brown-shimer S., and Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 1670-1674
6. Cok S.J., Acton S.J., and Morrison A.R. The proximal region of the 3′-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U. J. Biol. Chem. 278 (2003) 36157-36162
7. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., Patterson R.T., Stirling D.I., and Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 163 (1999) 380-386
8. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4082-4085
9. Dean J.L., Brook M., Clark A.R., and Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274 (1999) 264-269
10. DeWitt D.L., el-Harith E.A., Kraemer S.A., Andrews M.J., Yao E.F., Armstrong R.L., and Smith W.L. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265 (1990) 5192-5198
11. Dixon D.A., Kaplan C.D., Mclntyre T.M., Zimmerman G.A., and Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression: the role of the 3′-untranslated region. J. Biol. Chem. 275 (2000) 11750-11757
12. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108 (2001) 1657-1665
13. Eberhart C.E., Coffey R.J., Radhika A., Giadiello F.M., Ferrenbach S., and Dubois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
14. Fan X.C., and Steitz J.A. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15293-15298
15. 2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in IL-1β-treated human synovial fibroblasts. J. Biol. Chem. 276 (2001) 31720-31731
16. Frevel M.A.E., Bakheet T., Silva A.M., Hissong J.G., Khabar K.S.A., and Williams B.R.G. p38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol. Cell. Biol. 23 (2003) 425-436
17. Fujita J., Mestre J.R., Zeldis J.B., Subbaramaiah K., and Dannenberg A.J. Thalidomide and its analogue inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. 7 (2001) 3349-3355
18. Gallouzi I.E., Brennan C.M., Stenberg M.G., Swanson M.S., Eversole A., Maizels N., and Steitz J.A. HuR binding to cytoplasmic mRNA is perturbed by heat shock. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3073-3078
19. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7384-7388
20. Hla T., Bishop-Bailey D., Liu C.H., Schaefers H.J., and Trifan O.C. Cyclooxygenase-1 and -2 isoenzymes. Int. J. Biochem. Cell Biol. 31 (1999) 551-557
21. Inoue H., and Tanabe T. Transcriptional role of the NFκB site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. Biochem. Biophys. Res. Commun. 244 (1998) 143-148
22. Inoue H., Nanayama T., Hara S., Yokoyama C., and Tanabe T. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett. 350 (1994) 51-54
23. Jang B.C., Sanchez T., Schaefers H.J., Trifan O.C., Liu C.H., Creminon C., Huang C.K., and Hla T. Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J. Biol. Chem. 275 (2000) 39507-39515
24. Jin S.H., Kim T.I., Han D.S., Shin S.K., and Kim W.H. Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. Ann. N.Y. Acad. Sci. 973 (2002) 414-418
25. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268 (1993) 9049-9054
26. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mamcini J.A., and Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55 (1995) 2556-2559
27. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin Jr. A.S. Inhibition of NFκB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem. 276 (2001) 22382-22387
28. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64 (1997) 971-978
29. Kutchera W., Jones D.A., Matsunami N., Groden J., McIntyre T.M., Zimmerman G.A., White R.L., and Prescott S.M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4816-4820
30. Lasa M., Mahtani K.R., Finch A., Brewer G., Saklatvala J., and Clark A.R. Regulation of cyclooxygenase-2 mRNA stability by the MAPK p38 signaling cascade. Mol. Cell. Biol. 20 (2000) 4265-4274
31. Lasa M., Brook M., Saklatvala J., and Clark A.R. Dexamethasone destabilizes cyclooxygenase-2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol. Cell. Biol. 21 (2001) 771-780
32. Levy N.S., Chung S., Furneaux H., and Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273 (1998) 6417-6423
33. Little R.F., Wyvill K.M., Pluda J.M., Welles L., Marshall V., Figg W.D., Newcomb F.M., Tosato G., Feigal E., Steinberg S.M., Whitby D., Goedert J., and Yarchoan R. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 18 (2000) 2593-2602
34. McCarthy J.E. Posttranscriptional control of gene expression in yeast. Microbiol. Mol. Biol. Rev. 62 (1998) 1492-1553
35. Moller D.R., Wysocka M., Greenlee B.M., Ma X., Wahl L., Flockhart D.A., Trinchieri G., and Karp C.L. Inhibition of IL-12 production by thalidomide. J. Immunol. 159 (1997) 5157-5161
36. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on TNFá by enhancing mRNA degradation. J. Exp. Med. 177 (1993) 1675-1680
37. Morris J.K. An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells. J. Biol. Chem. 271 (1996) 16633-16643
38. Peng S.S., Chen C.Y., Xu N., and Shyu A.B. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J. 17 (1998) 3461-3470
39. Ridley S.H., Dean J.L., Sarsfield S.J., Brook M., Clark AR., and Saklatvala J.A. A p38 MAP kinase inhibitor regulates stability of IL-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 439 (1998) 75-80
40. Ristimaki A., Garfinkel S., Wessendorf J., Maciag T., and Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha: evidence for post-transcriptional regulation. J. Biol. Chem. 269 (1994) 11769-11775
41. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173 (1991) 699-703
42. Shaw G., and Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46 (1986) 659-667
43. Sheng H., Shao J., Dixon D.A., Williams C.S., Prescott S.M., DuBois R.N., and Beauchamp R.D. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275 (2000) 6628-6635
44. Sheng H., Shao J., and DuBois R.N. K-Ras-mediated increase in cyclooxygenase-2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 61 (2001) 2670-2675
45. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anassie E., Wilson C., Dhodapkar M., Zeldis J., and Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341 (1999) 1565-1571
46. Sirosis J., and Richards J.S. Transcriptional regulation of the rat prostaglandin endoperoxidase synthase 2 gene in granulosa cells: evidence for the role of a cis-acting C/EBP beta promoter element. J. Biol. Chem. 268 (1993) 21931-21938
47. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev. Biochem. 69 (2000) 145-182
48. Stephens T.D., and Fillmore B.J. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 61 (2000) 189-195
49. Tavares J.L., Wangoo A., Dilworth P., Marshall B., Kotecha S., and Shaw R.J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir. Med. 91 (1997) 31-39
50. Thomas B., Berenbaum F., Humbert L., Bian H., Bereziat G., Crofford L., and Olivier J.L. Critical role of C/EBPdelta and C/EBPbeta factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1 beta in articular chondrocytes. Eur. J. Biochem. 267 (2000) 6798-6809
51. Verheul H.M., Panigrahy D., Yuan J., and D'Amato R.J. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer 79 (1999) 114-118
52. Wang X., Campbell L.E., Miller C.M., and Proud C.G. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem. J. 334 (1998) 261-267
53. Wang W., Furneaux H., Cheng H., Caldwell M.C., Hutter D., Liu Y., Holbrook N., and Gorospe M. HuR regulates p21 mRNA stabilization by UV light. Mol. Cell. Biol. 20 (2000) 760-769
54. Xie W., Fletcher B.S., Anderson R.D., and Herschman H.R. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol. Cell. Biol. 14 (1994) 6531-6539
55. Xu K., Robida A.M., and Murphy T.J. Immediate-early MEK-1-dependent stabilization of rat smooth muscle cell cyclooxygenase-2 mRNA by Galpha(q)-coupled receptor signaling. J. Biol. Chem. 275 (2000) 23012-23019
56. Yamamoto K., Arakawa T., Ueda N., and Yamamoto S. Transcriptional roles of NFκB and NF-IL6 in the TNFα-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270 (1995) 31315-31320
57. Yokoyama C., and Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165 (1989) 888-894